Showing posts with label Cost ratio. Show all posts
Showing posts with label Cost ratio. Show all posts

Friday, 16 June 2023

Analysis of Cost Variance for Anti-Epileptic Medications from Various Manufacturers in the Indian Pharmaceutical Market | Chapter 4 | Novel Aspects on Pharmaceutical Research Vol. 3

 Drug-persuaded myopathy, a disease at which point taking certain drugs can diminish or destroy powers. Although the prevalence concerning this illness brought on for one drug Telmisartan is unknown, it is popular that 150 different pharmaceuticals, containing statins, corticosteroids, anti-retroviral situations, and immunosuppressants, have been linked to myotoxicity. Guidelines warn therapeutic drug listening, which is usually evaluating the levels of the medication in a patient's distribution, to manage the risk of drug-inferred myopathy linked to Telmisartan. Additionally, it concede possibility be highlighted that using Telmisartan is indulged with a slightest rise in blood creatinine, a synthetic produced by influence tissue, of up to 20–30%. However, it is considered to stop the therapy if the antitoxin creatinine level rises by more than 30%. The case defined in the paragraph involves a patient the one was thought to have knowledgeable an adverse drug reaction (ADR) to the hypertension treatment Telmisartan. The ADR with Telmisartan was driven to be "Probable" later conducting a origin analysis utilising Naranjo's treasure and the WHO-UMC Scale. As a result, the drug was removed and replaced accompanying Enalapril. The new drug helped the patient's condition, and after lab experiment revealed that the patient's levels of uric acid and creatinine were both inside normal ranges. The division focuses on how critical it is to closely monitor pharmacological medicine, especially when it includes prolonged use, so that protect victims. Myotoxicity, a rare but serious antagonistic drug reaction, was the particular ADR connected to the drug Telmisartan in this place instance. To prevent additional toxicity, Telmisartan was not administered to the patient repeated.

Author(s) Details:

Hansraj Kumar,
Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.

Please see the link here: https://stm.bookpi.org/NAPR-V3/article/view/10879



Monday, 20 September 2021

Study on Utilization Pattern of Anti Dementia Drugs and Cost-Effective Analysis in India | Chapter 13 | Current Aspects in Pharmaceutical Research and Development Vol. 2

 Background: In India, the number of people suffering from Alzheimer's disease (AD) and other dementias is expected to rise every year, owing to continuous growth in the elderly population and consistent increases in life expectancy. Aim: To assess the current state of clinical practise in India, as well as the cost of anti-dementia medications in the Indian context. Methods and Materials: A literature study and data mining of prospective and retrospective studies were used to investigate the pattern of anti-dementia drug use. In India, a cost analysis was conducted to determine the huge range of prices for the same anti-dementia medicine in different formulations. According to prospective and retrospective research, Alzheimer's disease is the most frequent subtype of dementia, and donepezil is still the most widely prescribed medicine. A cost analysis of anti-dementia medications manufactured by a variety of companies in India revealed a wide range of prices between the lowest and highest. Rivastigmine (1.5 mg capsule) had the highest cost-to-benefit ratio, whereas piracetam had the lowest (400 mg tablet). The percent cost variation of all anti-dementia medications was found to be greater than 100. Conclusion: In India, a large range of pricing for the same medicine in several formulations has a significant economic impact. More research is needed to better understand and assess the prescription and use patterns of anti-dementia medications, as they have a significant socioeconomic impact on patients and carers in developing countries such as India.

Author(s) Details

S. Ray
CSIR-National Institute of Science Communication and Policy Research (CSIR-NIScPR), formerly known as CSIR-National Institute of Science Technology and Development Studies (NISTADS), India.

View Book :- https://stm.bookpi.org/CAPRD-V2/article/view/3961